Opko Health Sets Revenue Goals for 2025

Published 10 hours agoOPK

Opko Health Sets Revenue Goals for 2025

Opko Health has unveiled its revenue forecasts for 2025, projecting total revenues to fall between $675 million and $700 million. The company's breakdown of this revenue expects services to bring in $400 million to $425 million, while product sales are anticipated to be between $165 million and $175 million. Additionally, other revenues, which include a Pfizer gross profit share and BARDA income, are estimated at $80 million to $95 million.

Reuters reported that the company's total costs and expenses for 2025 will likely range from $825 million to $875 million, not accounting for non-recurring charges related to the restructuring of BioReference Health. Research and development costs are projected to be $120 million to $140 million, with a portion offset by BARDA funding. Depreciation and amortization are expected to add up to $90 million.

Strategically, Opko Health aims to enhance its pharmaceutical pipeline and maintain significant R&D investments, working collaboratively with industry giants like Pfizer and Merck. The company is also actively seeking partnerships to further develop its product portfolio and boost its financial standing by the year 2025.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Visa Completes Exchange Offer for Class B-1 Stock Confidently

Visa Completes Exchange Offer for Class B-1 Stock Confidently

13 minutes agoV

Visa has successfully concluded its Exchange Offer for Class B-1 common stock, wrapping up the offer on May 6, 2024. The company announced the results following the offer's expiration on May 3, 2024. Notably, approximately 98% of outstanding Class B-1 shares participated, amounting to 240,677,470 shares, according to Visa's announcements. In the exchange, Visa issued 120,338,683 shares of Class B-2 common stock while also providing 47,759,832 shares of Class C common stock. Cash was offered in lieu of fractional shares, based on the closing price of Class A common stock, which was $268.49 on the expiration date. Crucially, Visa opted not to engage in any stabilization or manipulation of share prices during this offer period, as reported by contracts.justia.com. This strategic financial maneuver by Visa aimed to unlock liquidity for its shareholders by releasing transfer restrictions on its Class B stock. By doing so, Visa not only potentially reduces overhang risks but also showcases its ongoing commitment to market stability and reinforcing shareholder trust.

Apple Faces Legal Hurdle Over App Store Practices

Apple Faces Legal Hurdle Over App Store Practices

28 minutes agoAAPL

Apple Inc. encountered a major legal hurdle when U.S. District Judge Yvonne Gonzalez Rogers found the company in violation of a court order from April 30, 2025. The ruling stated that Apple impeded competition by imposing a 27% commission on external transactions and restricting links to external purchases. As a result, Apple's finance VP, Alex Roman, and the company were referred to federal prosecutors for potential criminal contempt, according to Reuters. In response to this decision, Epic Games, known for its ongoing antitrust confrontation with Apple, announced its intention to bring "Fortnite" back to the App Store. The decision is seen as a triumph for developers and consumers, marking a shift in the dynamics between Apple and third-party app developers. Meanwhile, Apple's stock saw a slight uptick, trading at $212.50 with a 0.544% increase from its previous close as of May 1, 2025. Apple has communicated its intent to appeal the ruling, though it has agreed to comply with the current court order in the meantime. The company remains at the center of discussions about fair competition practices, especially concerning how it manages the App Store, which has been a significant point of contention in its legal battles with app developers.

CVS Shares Surge 12% After CMA Ends Investigation

CVS Shares Surge 12% After CMA Ends Investigation

43 minutes agoCVS

Shares of CVS Group plc jumped by 12% after the UK’s Competition and Markets Authority (CMA) closed its investigation into the company. The probe, which began in May 2024, was part of a broader examination into the UK’s £5 billion veterinary sector, focusing on concerns about pricing and transparency. There were initial fears that the CMA might enforce stringent measures like capping prescription fees or demanding asset sell-offs, as reported by fool.co.uk. However, the situation took a positive turn as CVS offered to sell its subsidiary, The Vet, leading to the conclusion of the investigation. This move was formally accepted by the CMA, calming investor concerns and driving the recent surge in share price, as detailed on advfn.com. CVS has been strategically reshaping its portfolio, having already offloaded loss-making operations in the Netherlands and Republic of Ireland to concentrate on more profitable markets. According to lse.co.uk, CVS is steadfast in its growth ambitions, including plans to expand within the Australian veterinary market, while maintaining support for the CMA's ongoing sector review.

Ryanair May Look Beyond Boeing Amid Tariff Concerns

Ryanair May Look Beyond Boeing Amid Tariff Concerns

58 minutes agoBA

Ryanair CEO Michael O'Leary has indicated that the airline might explore alternatives to Boeing for its aircraft orders if U.S. tariffs significantly drive up costs. This development comes as Ryanair is completing its order of 210 Boeing 737 MAX jets, with 29 planes still expected by March of next year, according to Reuters. In addition to their current order, Ryanair holds 150 firm orders for the Boeing MAX 10 model, with options for 150 more, starting in 2027. Concerns have been raised about potential increases in aircraft prices due to U.S. tariffs, pushing Ryanair to consider other manufacturers. O'Leary mentioned that they haven't discussed with Chinese manufacturer COMAC since 2011, but would consider them if their planes were priced 10%-20% lower than those of Boeing's competitor Airbus. U.S. Representative Raja Krishnamoorthi has voiced concerns over the possibility of Ryanair purchasing Chinese-manufactured planes, citing potential national security risks. Meanwhile, Boeing is actively working to address Ryanair's concerns, focusing on improving the quality and delivery performance of the 737 model, as reported by Aeroxplorer.